title: Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs: the JAMP study.
abstract: BACKGROUND
  To investigate the ameliorating effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood glucose control in patients with type 2 diabetes mellitus who were previously untreated with or who have a poor responsive to existing antidiabetic drugs.
  
  
  METHODS
  Sitagliptin (50 mg/day) was added on to the pre-existing therapy for type 2 diabetes and changes in the glycated hemoglobin (HbA1c) level after 3 months of treatment were compared with the baseline and performed exploratory analysis.
  
  
  RESULTS
  HbA1c levels were significantly decreased after 1 month of treatment compared to baseline, with a mean change in HbA1c level from baseline of -0.73% (range, -0.80 to -0.67) in the entire study population at 3 months. Patients who received a medium dose of glimepiride showed the least improvement in HbA1c levels. The percentage of patients who achieved an HbA1c level of <7.0% significantly increased after 1 month of treatment, reaching 53.1% at 3 months. The percentage of patients who achieved a fasting blood glucose level of <130 mg/dL significantly increased after 1 month of treatment, reaching 50.9% at 3 months.
  
  
  CONCLUSIONS
  Sitagliptin improved the HbA1c level and rate of achieving the target control levels in patients with type 2 diabetes mellitus who were previously untreated with, or poorly responsive to, existing antidiabetic drugs. Thus, sitagliptin is expected to be useful in this patient group. However, the additional administration of sitagliptin in patients treated with medium-dose glimepiride only slightly improved blood glucose control when corrected for baseline HbA1c level.
authors.affiliation: Department of Medicine, Medical Center East, Tokyo Women's Medical University School of Medicine , 2-1-10 Nishiogu, Arakawa-ku, Tokyo, 116-8567, Japan. sakuragm@dnh.twmu.ac.jp.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Sakura
authors.affiliation: Department of Diabetes, Endocrine and Metabolic Diseases, Tokyo Women's Medical University Yachiyo Medical Center, 477-96, Owada-shinden, Yachiyo-shi, Chiba, 276-8524, Japan.
authors.forename: Naotake
authors.initials: N
authors.lastname: Hashimoto
authors.affiliation: Internal Medicine, Suzuki Clinic, 2-10-14, Koyasu-machi, Hachioji-shi, Tokyo, 192-0904, Japan.
authors.forename: Kazuo
authors.initials: K
authors.lastname: Sasamoto
authors.affiliation: Internal Medicine, Oyama East Clinic, 1-32-1, Ekihigashi-dori, Oyama-shi, Tochigi, 323-0022, Japan.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ohashi
authors.affiliation: Internal Medicine, Nishiyamado-Keiwa Hospital, 3247-1, Kounosu, Naka-shi, Ibaraki, 311-0133, Japan.
authors.forename: Sumiko
authors.initials: S
authors.lastname: Hasumi
authors.affiliation: Department of Medicine, Diabetes Center, Institute of Geriatrics, Tokyo Women's Medical University, Shibuya Cross Tower 22F, 2-15-1, Shibuya, Shibuya-ku, Tokyo, 150-0002, Japan.
authors.forename: Noriko
authors.initials: N
authors.lastname: Ujihara
authors.affiliation: Josai Hospital, 2-42-11, Kamiogi, Suginami-ku, Tokyo, 167-0043, Japan.
authors.forename: Tadasu
authors.initials: T
authors.lastname: Kasahara
authors.affiliation: Diabetes and Lifestyle Center, Tomonaga Clinic, Shinyon curumu Building 9F, 4-2-23, Shinjuku, Shinjuku-ku, Tokyo, 160-0022, Japan.
authors.forename: Osamu
authors.initials: O
authors.lastname: Tomonaga
authors.affiliation: Diabetes Center, Edogawa Hospital, Medical Plaza Shinozaki, SK Building, 7-15-12, Shinozaki-machi, Edogawa-ku, Tokyo, 133-0057, Japan.
authors.forename: Hideo
authors.initials: H
authors.lastname: Nunome
authors.affiliation: Nishikawa Clinic, 2-16-3, Towa, Adachi-ku, Tokyo, 120-0003, Japan.
authors.forename: Masashi
authors.initials: M
authors.lastname: Honda
authors.affiliation: The Institute for Adult Diseases, Asahi Life Foundation, Asahiseimeisunaga building, 2-2-6, Nihonbashi Bakuro-cho, Chuo-ku, Tokyo, 103-0002, Japan.
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Iwamoto
mesh_terms: D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000187:drug effects*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D004359:Drug Therapy, Combination; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D000068900:Sitagliptin Phosphate / Q000494:pharmacology* / Q000627:therapeutic use; D013453:Sulfonylurea Compounds / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D000068900:Sitagliptin Phosphate; D013453:Sulfonylurea Compounds; C517652:hemoglobin A1c protein, human; C057619:glimepiride
keywords: DPP-4 inhibitor; Diabetes mellitus; Glimepiride; HbA1c; Sitagliptin